Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Lymphoma
10/11/2020

Bone Marrow Transplant. 2020 Nov 10. doi: 10.1038/s41409-020-01099-4. Online ahead of print.

NO ABSTRACT